Posters/Publications

presentation

Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial

Keystone Symposia

Date - 04/2026

poster

Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial

Keystone Symposia

Date - 04/2026

poster

Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial

MASH TAG

Date - 01/2026

poster

Spatial Computational Histology Stratified Denifanstat Fibrosis Responders in the Phase 2b FASCINATE-2 MASH Trial

AASLD The Liver Meeting

Date - 11/2025

poster

Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial

AASLD The Liver Meeting

Date - 11/2025

poster

FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial

2025 Fall Clinical Dermatology Conference

Date - 10/2025

oral

Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASH

9th Annual MASH Drug Development Summit

Date - 09/2025

oral

Utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced Fibrosis

9th Annual MASH Drug Development Summit

Date - 09/2025

presentation

First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase 3 Randomised Placebo Controlled Trial

European Academy of Dermatology and Venereology (EADV) Congress 2025

Date - 09/2025

poster

Denifanstat improved multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk

EASL International Liver Congress

Date - 05/2025